In a recent publication in Molecular Therapy, researchers from Drexel University College of Medicine and UMass Chan Medical ...

Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the ...

The U.S. FDA dashed hopes that Corcept Therapeutics Inc. might be able to launch its selective glucocorticoid receptor ...

The U.S. FDA recently cleared Medtronic plc’s Hugo robotic-assisted surgery system and CMR Surgical Ltd.’s Versius Plus ...

Guangzhou Runer Ophthalmic Biotechnology Co. Ltd. has identified complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, asthma, ...

If the 2025 U.S. life sciences regulatory scene were to be summed up in one word, it would have to be uncertainty. Two words might be more definitive – chaotic uncertainty.

On the last day of the year, shares of Axsome Therapeutics Inc. rose 22% on news that the U.S. FDA accepted and granted priority review of the company’s supplemental NDA for AXS-05 to treat ...

The receptor tyrosine kinase-like orphan 1 (ROR1) is a transmembrane protein expressed during embryonic development. Moreover, it is highly expressed on the surface of several cancer cell types, ...

Wife-and-husband team, J. Jean Cui and Y. Peter Li, launched Blossomhill Therapeutics Inc. in mid-2020 to focus on next-generation, macrocyclic inhibitors against oncology targets. The couple had ...

SYNGAP1-related disorders (SRDs) are rare neurodevelopmental conditions characterized by a wide range of symptoms, including intellectual disability, epilepsy, motor deficits and increased risk-taking ...

Jiangsu Carephar Pharmaceutical Co. Ltd. has divulged angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of idiopathic pulmonary fibrosis.

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, ...